Compare Sprott Uranium Miners ETF (URNM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sprott Uranium Miners ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Sprott Uranium Miners ETF trades at $50.32, while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| URNM | VRTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $83.99 | $529.59 |
52-Week Low | $44.14 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URNM trades at $48.25 with minimal daily movement (+0.06%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though RSI suggests potential oversold conditions. Recent news highlights uranium's role in AI power demand, with nuclear energy positioned as a solution to data center electricity needs. The fund has gained significant attention for its pure-play uranium miner exposure versus broader nuclear ETFs.
The uranium sector faces a favorable long-term outlook with projected nuclear demand tripling by 2050, though current technical weakness and concentration risks in mining companies present near-term challenges. URNM offers leveraged exposure to uranium price movements but remains vulnerable to sector volatility and supply chain constraints.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
